Clinical Trials Browser

Phase 3 × Neuroendocrine Tumors × 90 days × Clear all

Fibrosarcoma, Hyperinsulinism, Hypoglycemia, Insulinoma, Adenoma, Islet Cell, Liposarcoma, Neoplasms, Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

NCT00569127 2026-04-13

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Phase 3 Active not recruiting

427 enrolled 17 charts

EndocrineNET

Neuroendocrine Tumors

NCT03375320 2026-04-13

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

Phase 3 Active not recruiting

298 enrolled 14 charts 3 FDA

EndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT03049189 2026-04-06

COMPETE

Phase 3 Active not recruiting

324 enrolled 15 charts

EndocrineNET

Neuroendocrine Tumors

NCT05477576 2026-03-30

ACTION-1

Phase 3 Recruiting

338 enrolled

EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors

NCT07087054 2026-03-10

CAREFNDR

Phase 3 Recruiting

141 enrolled

EndocrineNET

Carcinoid Tumors, Intestinal, Carcinoid Tumor, Neuroendocrine Tumors, Serotonin Syndrome

NCT04810091 2026-03-09

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

Phase 3 Active not recruiting

79 enrolled 24 charts

EndocrineNET

Neuroendocrine Tumors

NCT05918302 2026-03-06

LEVEL

Phase 3 Recruiting

120 enrolled

EndocrineNET

Thymus Neoplasms, Neuroendocrine Tumors

NCT04706910 2026-02-09

18F-DOPA II - PET Imaging Optimization

Phase 3 Recruiting

800 enrolled

CNSEndocrineNET

Brain Neoplasms, Neuroblastoma, Parkinson Disease, Neuroendocrine Tumors, Lewy Body Disease, Congenital Hyperinsulinism

Clinical Trials

Tumor HI

Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors

COMPETE

ACTION-1

CAREFNDR

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

LEVEL

18F-DOPA II - PET Imaging Optimization